Trial Profile

A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2020 Updated results of progression-free survival (PFS) and final results of overall survival (OS) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
14 May 2020 According to a PharmaMar media release, data from this trial will be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29th to June 2nd , 2020.
15 May 2014 A results of this study assessing the association between febrile neutropenia and skeletal muscle mass (SMM) and skeletal muscle densities (SMD) presented at the 2014 Annual Meeting of the ASCO, according to a PharmaMar media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com